The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Sanofi
First-in-human phase 1 study of the antibody-drug conjugate (ADC) SAR408701 in advanced solid tumors: Dose-expansion cohort of patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC).
 
Anas Gazzah
No Relationships to Disclose
 
Sophie Cousin
No Relationships to Disclose
 
Valentina Boni
Honoraria - Loxo
Consulting or Advisory Role - Guidepoint Global; OncoArt
Speakers' Bureau - Solti
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Incyte (Inst); Janssen Oncology (Inst); Kura Oncology (Inst); Lilly (Inst); Loxo (Inst); Menarini (Inst); Merck (Inst); Merus (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Synthon (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - START
 
Charles Ricordel
No Relationships to Disclose
 
Tae Min Kim
Research Funding - AstraZeneca
 
Jin-Soo Kim
Stock and Other Ownership Interests - Chong Kun Dang Pharmaceutical; DAEHWA Pharmaceutical
Honoraria - Boehringer Ingelheim; CJ Healthcare; Lilly; Merck
Consulting or Advisory Role - CJ Healthcare; DAEHWA Pharmaceutical; Lilly
Research Funding - Alpha Biopharma; ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Chong Kun Dang Pharmaceutical; CJ Healthcare; Five Prime Therapeutics; Hanmi; Lilly; Merck; Novotech; Ono Pharmaceutical; Pfizer; Sanofi; Yuhan
Expert Testimony - CJ Healthcare
Travel, Accommodations, Expenses - Boehringer Ingelheim
 
Carole Helissey
Consulting or Advisory Role - Astellas Pharma; Janssen; Sanofi
Travel, Accommodations, Expenses - Astellas Pharma
 
Itziar Gardeazabal
No Relationships to Disclose
 
Mustapha Chadjaa
No Relationships to Disclose
 
Aurore Allard
Employment - Sanofi
Stock and Other Ownership Interests - Sanofi
 
Semra Yoruk
Employment - Sanofi
Stock and Other Ownership Interests - Sanofi
 
Fabrice Barlesi
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Pfizer; Pierre Fabre; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche; Takeda
Research Funding - Abbvie (Inst); ACEA Biosciences (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Eisai (Inst); Genentech/Roche (Inst); Ignyta (Inst); Innate Pharma (Inst); Ipsen (Inst); Lilly (Inst); Loxo (Inst); Medimmune (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi (Inst); Takeda (Inst)